Penumbra (NYSE:PEN) Director Thomas Wilder Sells 186 Shares of Stock

Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 186 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $253.93, for a total transaction of $47,230.98. Following the sale, the director directly owned 186 shares of the company’s stock, valued at $47,230.98. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Thomas Wilder also recently made the following trade(s):

• On Tuesday, August 12th, Thomas Wilder sold 372 shares of Penumbra stock. The shares were sold at an average price of $240.16, for a total transaction of $89,339.52.

Penumbra Trading Up 1.0%

Shares of NYSE:PEN opened at $256.05 on Friday. The firm has a fifty day moving average of $257.64 and a two-hundred day moving average of $262.97. The firm has a market capitalization of $9.99 billion, a P/E ratio of 68.10, a price-to-earnings-growth ratio of 2.29 and a beta of 0.41. Penumbra, Inc. has a 12-month low of $190.08 and a 12-month high of $310.00. The company has a quick ratio of 4.04, a current ratio of 6.75 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, July 29th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.05. The company had revenue of $339.46 million during the quarter, compared to analyst estimates of $327.37 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The company’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter last year, the business posted $0.64 EPS. Penumbra has set its FY 2025 guidance at EPS. On average, equities analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PEN shares. Royal Bank Of Canada decreased their target price on shares of Penumbra from $330.00 to $325.00 and set an “outperform” rating for the company in a research note on Wednesday, July 30th. Citigroup decreased their target price on shares of Penumbra from $320.00 to $285.00 and set a “neutral” rating for the company in a research note on Wednesday, July 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a research note on Saturday, September 27th. Robert W. Baird lifted their price objective on shares of Penumbra from $283.00 to $285.00 and gave the company an “outperform” rating in a research note on Wednesday, July 30th. Finally, William Blair raised shares of Penumbra to a “strong-buy” rating in a research note on Friday, July 18th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Penumbra currently has an average rating of “Moderate Buy” and an average price target of $302.93.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in Penumbra by 7.3% in the second quarter. GAMMA Investing LLC now owns 761 shares of the company’s stock valued at $195,000 after acquiring an additional 52 shares during the period. Fifth Third Bancorp increased its stake in Penumbra by 16.4% in the first quarter. Fifth Third Bancorp now owns 404 shares of the company’s stock valued at $108,000 after acquiring an additional 57 shares during the period. Parkside Financial Bank & Trust increased its stake in Penumbra by 70.2% in the second quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock valued at $41,000 after acquiring an additional 66 shares during the period. Quadrant Capital Group LLC increased its stake in Penumbra by 2.9% in the second quarter. Quadrant Capital Group LLC now owns 2,872 shares of the company’s stock valued at $737,000 after acquiring an additional 82 shares during the period. Finally, First Horizon Advisors Inc. increased its stake in Penumbra by 404.8% in the first quarter. First Horizon Advisors Inc. now owns 106 shares of the company’s stock valued at $28,000 after acquiring an additional 85 shares during the period. Institutional investors and hedge funds own 88.88% of the company’s stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.